Living

US FDA approves AbbVie's rare blood cancer drug

By Reuters Reuters
Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration
Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration DADO RUVIC Reuters

The U.S. Food and Drug Administration on Wednesday approved AbbVie's drug to treat blastic plasmacytoid dendritic cell neoplasm, a very rare type of blood cancer.

(Reporting by Sahil Pandey in Bengaluru; Editing by Shreya Biswas)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published May 27, 2026 at 12:33 PM.

Get one year of unlimited digital access for $159.99
#ReadLocal

Only 44¢ per day

SUBSCRIBE NOW